2nd May 2025 12:00
Abingdon Health plc
("Abingdon Health", the "Group" or the "Company")
Award of Options under LTIP
York, U.K. 2 May 2025: Abingdon Health plc (AIM: ABDX), a leading international developer, manufacturer and distributor of high quality and effective rapid tests, announces that, under the terms of the existing Long Term Incentive Plan established in December 2022 ("LTIP" or the "Plan"), the Company has awarded share options ("Options") over a total of 4,092,000 ordinary shares of 0.025 pence each ("Ordinary Shares") to certain directors and senior management, in order to incentivise and encourage retention in a manner that aligns with the interests of the Company's shareholders.
The Options are nil cost and will vest over the period to 30 June 2027. Vesting of the Options is conditional upon the business achieving certain challenging total shareholder return criteria.
The following directors and members of the senior management team (each a person discharging managerial responsibilities ("PDMR")) have been awarded options:
PDMR | Role | No. of new Options awarded under the LTIP | No. of existing Options under the LTIP | Total number of Options under the LTIP |
Chris Hand | Executive Chairman | 946,000 | 712,057 | 1,658,057 |
Chris Yates | Chief Commercial Officer / President, Abingdon Health USA Inc | 946,000 | 2,136,173 | 3,082,173 |
Tom Hayes | Chief Financial Officer | 660,000 | - | 660,000 |
Mark Jones | Chief Operating Officer | 500,000 | 1,001,376 | 1,501,376 |
Nina Garrett | Chief Technical Officer | 420,000 | 852,156 | 1,272,156 |
Candice Vendettuoli | Head of QARA | 320,000 | 469,200 | 789,200 |
Natalie Thrush | Head of HR / Site Lead | 300,000 | 158,807 | 458,807 |
Enquiries:
Abingdon Health plc | www.abingdonhealth.com/investors/ | ||
Chris Hand, Executive Chairman
| Via Walbrook PR | ||
Tom Hayes, CFO
| |||
Zeus (Sole Broker and Nominated Adviser) | Tel: +44 (0)20 3829 5000 | ||
Antonio Bossi / Alexandra Campbell-Harris (Corporate Finance) | |||
Fraser Marshall (Corporate Broking)
|
| ||
Walbrook PR (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or [email protected] | ||
Paul McManus / Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 | ||
About Abingdon Health plc
Abingdon Health is a leading med-tech contract service provider offering its services to an international customer base.
The Group's CDMO division offers lateral flow product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health's CDMO division has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine and large-scale manufacturing; from "idea to commercial success".
Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Our consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internally (e.g. Quality Management Systems) and externally (e.g. critical suppliers), management reviews and presentations, training and mentoring.
Abingdon Simply TestTM range of self-tests are marketed via an e-commerce platform that offers a range of self-tests to empowers consumers to manage their own health and wellbeing. The Abingdon Simply TestTM e-commerce site offers consumers a range of information to support them in making informed decisions on the tests available. In addition, the site provides Abingdon's contract services customers with a potential route to market for self-tests. The Abingdon Simply Test range and other selected self-test products, such as the saliva pregnancy test, SalistickTM, is also sold through international distributors and through other channels in the UK and Ireland, such as pharmacy chains.
Founded in 2008, Abingdon Health is headquartered in York, England with CDMO facilities in both York, UK and Madison, Wisconsin, USA. For more information visit: www.abingdonhealth.com
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: | Chris Hand | |||
2 | Reason for the notification | ||||
a) | Position/Status:
| Executive Chairman | |||
b) | Initial Notification/Amendment:
| Initial Notification | |||
3 | Details of the issuer, emission allowance market participation, auction platform, auctioneer or auction monitor | ||||
a) | Name: | Abingdon Health plc | |||
b) | LEI: |
| |||
4. | Details of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted. | ||||
a) | Description of the financial instrument:
Identification code: | Ordinary Shares of 0.025 pence each
GB00BLF79J41 | |||
b) | Nature of the transaction:
| Award of LTIP Options | |||
c) | Price(s) and volume(s): | Price(s) | Volume(s) | ||
Nil | 946,000 | ||||
d) | Aggregated volume: Price: | See above | |||
e) | Date of the Transaction: | 2 May 2025 | |||
f) | Place of the Transaction: | Outside a trading venue | |||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: | Chris Yates | |||
2 | Reason for the notification | ||||
a) | Position/Status:
| Chief Commercial Officer / President, Abingdon Health USA Inc | |||
b) | Initial Notification/Amendment:
| Initial Notification | |||
3 | Details of the issuer, emission allowance market participation, auction platform, auctioneer or auction monitor | ||||
a) | Name: | Abingdon Health plc | |||
b) | LEI: |
| |||
4. | Details of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted. | ||||
a) | Description of the financial instrument:
Identification code: | Ordinary Shares of 0.025 pence each
GB00BLF79J41 | |||
b) | Nature of the transaction:
| Award of LTIP Options | |||
c) | Price(s) and volume(s): | Price(s) | Volume(s) | ||
Nil | 946,000 | ||||
d) | Aggregated volume: Price: | See above | |||
e) | Date of the Transaction: | 2 May 2025 | |||
f) | Place of the Transaction: | Outside a trading venue | |||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: | Tom Hayes | |||
2 | Reason for the notification | ||||
a) | Position/Status:
| Chief Financial Officer | |||
b) | Initial Notification/Amendment:
| Initial Notification | |||
3 | Details of the issuer, emission allowance market participation, auction platform, auctioneer or auction monitor | ||||
a) | Name: | Abingdon Health plc | |||
b) | LEI: |
| |||
4. | Details of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted. | ||||
a) | Description of the financial instrument:
Identification code: | Ordinary Shares of 0.025 pence each
GB00BLF79J41 | |||
b) | Nature of the transaction:
| Award of LTIP Options | |||
c) | Price(s) and volume(s): | Price(s) | Volume(s) | ||
Nil | 660,000 | ||||
d) | Aggregated volume: Price: | See above | |||
e) | Date of the Transaction: | 2 May 2025 | |||
f) | Place of the Transaction: | Outside a trading venue | |||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: | Mark Jones | |||
2 | Reason for the notification | ||||
a) | Position/Status:
| Chief Operating Officer | |||
b) | Initial Notification/Amendment:
| Initial Notification | |||
3 | Details of the issuer, emission allowance market participation, auction platform, auctioneer or auction monitor | ||||
a) | Name: | Abingdon Health plc | |||
b) | LEI: |
| |||
4. | Details of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted. | ||||
a) | Description of the financial instrument:
Identification code: | Ordinary Shares of 0.025 pence each
GB00BLF79J41 | |||
b) | Nature of the transaction:
| Award of LTIP Options | |||
c) | Price(s) and volume(s): | Price(s) | Volume(s) | ||
Nil | 500,000 | ||||
d) | Aggregated volume: Price: | See above | |||
e) | Date of the Transaction: | 2 May 2025 | |||
f) | Place of the Transaction: | Outside a trading venue | |||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: | Nina Garrett | |||
2 | Reason for the notification | ||||
a) | Position/Status:
| Chief Technical Officer | |||
b) | Initial Notification/Amendment:
| Initial Notification | |||
3 | Details of the issuer, emission allowance market participation, auction platform, auctioneer or auction monitor | ||||
a) | Name: | Abingdon Health plc | |||
b) | LEI: |
| |||
4. | Details of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted. | ||||
a) | Description of the financial instrument:
Identification code: | Ordinary Shares of 0.025 pence each
GB00BLF79J41 | |||
b) | Nature of the transaction:
| Award of LTIP Options | |||
c) | Price(s) and volume(s): | Price(s) | Volume(s) | ||
Nil | 420,000 | ||||
d) | Aggregated volume: Price: | See above | |||
e) | Date of the Transaction: | 2 May 2025 | |||
f) | Place of the Transaction: | Outside a trading venue | |||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: | Candice Vendettuoli | |||
2 | Reason for the notification | ||||
a) | Position/Status:
| Head of QARA | |||
b) | Initial Notification/Amendment:
| Initial Notification | |||
3 | Details of the issuer, emission allowance market participation, auction platform, auctioneer or auction monitor | ||||
a) | Name: | Abingdon Health plc | |||
b) | LEI: |
| |||
4. | Details of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted. | ||||
a) | Description of the financial instrument:
Identification code: | Ordinary Shares of 0.025 pence each
GB00BLF79J41 | |||
b) | Nature of the transaction:
| Award of LTIP Options | |||
c) | Price(s) and volume(s): | Price(s) | Volume(s) | ||
Nil | 320,000 | ||||
d) | Aggregated volume: Price: | See above | |||
e) | Date of the Transaction: | 2 May 2025 | |||
f) | Place of the Transaction: | Outside a trading venue | |||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: | Natalie Thrush | |||
2 | Reason for the notification | ||||
a) | Position/Status:
| Head of HR / Site Lead | |||
b) | Initial Notification/Amendment:
| Initial Notification | |||
3 | Details of the issuer, emission allowance market participation, auction platform, auctioneer or auction monitor | ||||
a) | Name: | Abingdon Health plc | |||
b) | LEI: |
| |||
4. | Details of transaction(s); section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted. | ||||
a) | Description of the financial instrument:
Identification code: | Ordinary Shares of 0.025 pence each
GB00BLF79J41 | |||
b) | Nature of the transaction:
| Award of LTIP Options | |||
c) | Price(s) and volume(s): | Price(s) | Volume(s) | ||
Nil | 300,000 | ||||
d) | Aggregated volume: Price: | See above | |||
e) | Date of the Transaction: | 2 May 2025 | |||
f) | Place of the Transaction: | Outside a trading venue | |||
Related Shares:
Abingdon Healt.